4//SEC Filing
Esperion Therapeutics, Inc. 4
Accession 0001179110-13-011142
$ESPRCIK 0001434868operating
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:33 PM ET
Size
22.2 KB
Accession
0001179110-13-011142
Insider Transaction Report
Form 4
SCHIFF ANDREW N
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying) - Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying)
Purcell Dennis J
10% Owner
Transactions
- Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying)
ELMS STEVE
10% Owner
Transactions
- Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying)
Aisling Capital II LP
10% Owner
Transactions
- Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying) - Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.)
AISLING CAPITAL PARTNERS, LP
10% Owner
Transactions
- Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying) - Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying)
AISLING CAPITAL PARTNERS LLC
10% Owner
Transactions
- Purchase
Common Stock
2013-07-01$14.00/sh+238,119$3,333,666→ 2,054,594 total(indirect: By Aisling Capital II, L.P.) - Other
Warrant to Purchase Preferred Stock
2013-07-01−497,666→ 0 total(indirect: By Aisling Capital II, L.P.)Exercise: $1.00Exp: 2018-02-12→ Series A Preferred Stock (497,666 underlying) - Other
Warrant to Purchase Common Stock
2013-07-01+71,237→ 71,237 total(indirect: By Aisling Capital II, L.P.)Exercise: $6.99Exp: 2018-02-12→ Common Stock (71,237 underlying) - Conversion
Common Stock
2013-07-01+1,816,475→ 1,816,475 total(indirect: By Aisling Capital II, L.P.) - Conversion
Series A Preferred Stock
2013-07-01−1,816,475→ 0 total(indirect: By Aisling Capital II, L.P.)→ Common Stock (1,816,475 underlying)
Footnotes (4)
- [F1]The Series A Preferred Stock was automatically converted into Common Stock on a 6.986-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
- [F2]The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.
- [F3]The warrant is immediately exercisable.
- [F4]Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price automatically adjusted accordingly. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrant and the change in exercise price.
Documents
Issuer
Esperion Therapeutics, Inc.
CIK 0001434868
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001434868
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 4:33 PM ET
- Size
- 22.2 KB